bluuebunny/crossref_metadata_2025_split huggingface dataset:
(31) THE IMPACT OF SEXUAL VIOLENCE ON QUALITY OF LIFE AND MENTAL WELL-BEING OF TRANSGENDER AND GENDER DIVERSE INDIVIDUALS
Authors: Aisa Burgwal , Prof. Joz Motmans 
Published: July 2023

Abstract

Objectives
Transgender (trans) and gender diverse (GD) individuals have remained largely invisible in health research. Previous research shows worse outcomes on health indicators for trans people when compared to cisgender controls. Research on the impact of sexual violence focuses on mainly cisgender female victims. This study assessed the impact of sexual violence on quality of life (QoL) and mental well-being among trans and GD individuals.

Methods
An online, anonymous survey was conducted between Oct/21 and Jan/22 in Belgium. QoL and well-being were analyzed for differences between trans and GD victims of sexual violence versus non-victims. A backward regression analysis was applied, attempting to obtain a sexual violence model to explain significant differences in health-related outcomes. The effects of multiple control variables (gender identity, sexual orientation, age, income, ...) were taken into account within the modeling approach.

Results
The sample consisted of 310 respondents aged 15 years and older, with 107 (34.5%) transgender respondents and 203 (65.5%) GD respondents. 71.6% reported experiences with sexual violence over the past two years (n = 166). The backward regression analyses showed that sexual violence did not significantly impact QoL (p = .536), but it did have a significant impact on mental well-being (GHQ-12, p = .001). Other variables proved to be of importance in predicting QoL, such as age, socio-economic status, employment, relationship status, and living according to one’s own gender identity. Sexual violence predicted a significantly higher score on the GHQ-12 and thus predicted more psychological problems. Also age predicted mental well-being.

Conclusions
In understanding health disparities among trans and GD people, it is necessary to take into account the additive effect of multiple socio-economic positions. The high proportion of sexual violence, as well as the lower average QoL and mental well-being outcomes among trans and GD people compared to general population statistics, highlights the need for policy makers to create inclusive environments.

Conflicts of Interest
We hereby declare that there is no conflict of interest by submitting this abstract. The abstract and presentation are completely free from commercial influence or bias.
(91) INTRACAVERNOSAL AVIPTADIL WITH PHENTOLAMINE MESYLATE AS AN ALTERNATIVE TREATMENT FORREFRACTORY ERECTILE DYSFUNCTION
Authors: Fiona Holden , Clare Akers , Prof. David Ralph , Gin Lee Wai 
Published: July 2023

Abstract

Objectives
Vasoactive intestinal peptide (aviptadil) with phentolamine mesylate (Invicorp) was first used for erectile dysfunction (ED) in 1992. The advent of oral phosphodiesterase-5 inhibitors and the availability of intracavernosal alprostadil injections (ICAI) compounded by regulatory issues for Invicorp have limited the use and availability of this medication. Invicorp causes less pain on injection and may have a role following failure of ICAI but contemporary experience is limited.

Methods
Single centre retrospective review of all patients referred for trial of Invicorp after failing ICAI due to pain or poor efficacy following titration to at least 40mcg. The first injection was performed in clinic with either a half (12.5mg aviptadil/1mg phentolamine) or full (25mg aviptadil/2mg phentolamine) dose followed by a telephone call in 6 weeks. Efficacy was assessed by patient history after 3 months.

Results
163 men with a median age of 60 years (IQR 53-67) were referred after failing median ICAI dose of 20mcg (IQR 10-40). Aetiology of ED was post radical prostatectomy in 49% and diabetes in 31.9%. All men had failed oral phosphodiesterase-5 inhibitors and 75% found vacuum erection devices inadequate. 61% found ICAI too painful and were unable to titrate their dose higher while others reported poor response. Almost two-thirds (63.2%) found Invicorp effective and allowed sexual activity to resume (Table 1). Some (15%, n=24) stopped Invicorp despite good efficacy because they wanted to stop using injectables or experienced improvement in their erectile function over time (post radical prostatectomy). Fifty-three (32.5%) men developed adverse reactions following injection, primarily facial flushing (92%). No episodes of iatrogenic priapism were reported.

Conclusions
Invicorp offers an effective and acceptable third line option for men who have failed most non-surgical treatment for ED in the largest study to date. Many (63%) were given an alternative to penile prosthesis insertion by being offered Invicorp. Invicorp was well-tolerated and only 4 patients in this cohort (2.5%) stopped due adverse effects.

Conflicts of Interest
Nil
(182) THE EFFECT OF THE NEW 75 MG ORODISPERSIBLE FILM OF SILDENAFIL ON ERECTION AND SEXUAL QUALITY OF LIFE: INSIGHTS FROM AN OBSERVATIONAL STUDY.
Authors: Dr. Andrea Sansone , Dr. Valeria Frangione , Dr. Arturo Lanzarotti , Dr. Andrea Cocci , Dr. Carlo Ceruti , Prof. Marco De Sio , Prof. Ciro Imbimbo , Prof. Vincenzo Mirone , Prof. Luigi Schips , Prof. Carlo Terrone , Prof. Emmanuele A Jannini 
Published: July 2023

Abstract

Objectives
We investigated the effects of the sildenafil orodispersible film (ODF) 75 mg dose on both sexual quality of life and erectile function based on the results from an observational study in daily practice in Italy.

Methods
This was a post-hoc analysis of results from an observational, real-life study carried out in six centers in Italy on ED patients. All subjects were asked to take the prescribed dosage of Sildenafil ODF at inclusion (Visit 1) and to return for a control visit (Visit 2) to confirm or adapt the prescribed dose after a minimum of 4 weeks. An End of study Control visit (Visit 3) was performed after additional 4 weeks. Erectile function was assessed by the International Index of Erectile Function – Erectile Function Domain (IIEF-EF); sexual quality of life was measured using the sexual QoL instrument for men (SQoL-M).

Results
Among the 36 subjects initially recruited for the 75 mg dose, five patients dropped out of the study (2 at visit 2 and 3 at visit 3), none of which due to treatment inefficacy or serious adverse events. At visit 2, the mean IIEF-EF scores significantly increased (∆ = 7.97±4.71, p &lt;0.0001) as SQoL-M scores also did (∆ = 10.76±10.46, p &lt;0.0001). At visit 3, IIEF-EF and SQoL-M scores were still significantly improved compared to baseline (∆ = 10.64±7.01, p &lt;0.0001 and ∆ = 18.15±12.32, p &lt;0.0001, respectively). By ANCOVA, we found no significant effect for age, BMI, previous use of PDE5i, presence of metabolic comorbidities, and smoking habits on study outcomes at both visits 2 and 3.

Conclusions
The use of the ODF formulation for sildenafil represents an effective and safe novel opportunity to take care of ED patients, significantly improving both erectile function and sexual quality of life in patients undergoing treatment.

Conflicts of Interest
AS has been a consultant for Menarini. EAJ is/has been a consultant and/or paid speaker for Bayer, IBSA, Menarini, Merck-Serono, Otsuka, Pfizer Inc, Shionogi, and Viatris. VF and AL are full-time employees of IBSA. AC has no conflicts of interest. CC has been a consultant and/or paid speaker for Dompè Primary, Menarini, Takeda, Alphremev, SOFAR. MDS is/has been paid speaker for Janssen, Astellas, Leonardo Medica. CI has no conflicts of interest. VM has been a consultant and/or paid speaker for SR, Recordati, Janssen. LS has no conflicts of interest. CT has no conflicts of interest.
(312) PLATELET-RICH PLASMA (PRP) TREATMENT AND PENILE REJUVENATION IN PATIENTS WITH ERECTILE DYSFUNCTION: THE ROLE OF MEAN PLATELET VOLUME
Authors: Dr. Davide Francomano , Prof. Federico Dehò , Prof. Paolo Capogrosso , Prof. Sandro La Vignera , Prof. Gabriele Antonini , Prof. Antonio Aversa 
Published: July 2023

Abstract

Objectives
Erectile dysfunction (ED) is one a common disorder in adult males and current therapies are symptomatic and do not influence disease progression. By contrast, regenerative medicine may potentially reverse or stop the progression of ED and restore erectile capacity. We aimed to evaluate the clinical correlates of platelet function before platelet-rich plasma (PRP) injection and its potential efficacy in men with vascular ED poorly respondent to PDE5i.

Methods
To this purpose, 150 patients (Age: 51±16.7; mean IIEF5: 12±2.6; mean PSV: 32±5.5; Mean MPV=9.3±1.1) were submitted to a single-shot treatment of PRP. All patients were evaluated at baseline for mean platelet volume (MPV), and at baseline and 1 month after treatment for IIEF5 and dynamic penile duplex ultrasound (d-PDU) according to Aversa et al (Andrology, 2021; 9:1457-1466).

Results
All patients had a significant improvement in ED symptoms (IIEF5: 12±2.6 vs 19±3.0; p&lt;0.0001) and a significant improvement at d-PDU (PSV: 32±5.5 vs 42±7.6; p&lt;0.0001). The ROC analysis showed a significant accuracy (72.1%, C.I.64.0 - 80.2, p &lt;0.0001) for MPV in identifying men clinically responding to PRP with favourable outcomes (+4 points in IIEF5 score). In particular, an MPV&lt;8.95 was recognized as the best threshold with a sensitivity of 90% and specificity of 54.1%.

Conclusions
This study provides the first evidence that PRP outcomes correlate with baseline MPV in patients with ED and poorly responding to PDE5i. MPV below 8.95 identify patients with lower response to treatment that might benefit of re-treatment.

Conflicts of Interest
None
(200) PEYRONIE'S DISEASE SURGERY GRAFTING AREA REDUCTION: A COMPARATIVE ASSESSMENT BETWEEN IGRAFTER APP VS DOUBLE Y USING VALIDATED LOW-COST 3D-PRINTED PENILE MODELS
Authors: Prof. Bruno Machado , Alexandre Miranda , Eduardo Miranda , Prof. Bruno Nascimento 
Published: July 2023

Abstract

Objectives
Compare 2 PIG techniques, the iGrafter and Double-Y in 3 main aspects: I) Total grafting area; II) The variation in calculating the grafting to be used; III) time to perform the PIG.

Methods
Six urologists with expertise in sexual medicine performed both techniques twice using four 3-D vali-dated training models for PD with a standard 60° uniplanar dorsal curvature.

Results
For all surgeons, the use of iGrafter resulted in 2 grafts, for the Double Y technique in 1 graft. The Total Time of surgery was significantly longer for the iGrafter than for DY technique: 49 min +/- 11 min vs 40.7 min +/-5.7 min, respectively (P = 0.02). The iGrafter grafting area was significantly smaller to the Double Y technique (11.6 cm2 +/- 1.2 cm2 vs 23.3 cm2 +/- 5.4 cm2, respectively (P = 0.01), representing a 50.2% grafting area reduction for the iGrafter when compared to the DY. The variation of graft area, using the iGrafter also yielded a more consistent graft across all surgeons when compared to the DY technique (CV = 10.56% for the iGrafter vs 23.28% for the DY).

Conclusions
Using the iGrafter software for PIG surgery has shown to be a promising technique for severe Peyronie's Disease management resulting in smaller graft size (about 50% smaller when compared to the DY) which can potentially mean less erectile dysfunction for the patients operated by this technique.

Conflicts of Interest
The Authors have no conflict of interest.
(235) COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR THE TREATMENT OF PEYRONIE'S DISEASE – A SINGLE CENTRE EXPERIENCE
Authors: Dr. Dejan Bratus , Uros Bele , Tina Bratus 
Published: July 2023

Abstract

Objectives
Several conservative treatments have been tried for the treatment of Peyronie's disease in the last decades. All of them have failed to show significant efficacy in placebo controlled trials. Intralesional application of collagenase Clostridium histolyticum (Xiapex®) is one of the newer treatment possibilities and was introduced with a hope that it would reduce the number of men requiring surgery for this condition. Xiapex® consists of a mixture of purified class I and class II collagenases which cause enzymatic disruption of the fibrotic plaque by synergistically hydrolyzing the triple helical conformation of types I and III collagen. It also down regulates many of the growth factors, genes and cytokines that are involved in the pathogenesis of Peyronie's disease.

Methods
22 patients with diagnosed Peyronie’s disease were treated and the applications of collagenase Clostridium histolyticum were performed by two urologists. The inclusion criteria were diagnosed Peyronie’s disease with a fibrotic plaque causing the penile curvature between 30° and 60°. All patients were treated with two cycles of collagenase Clostridium histolyticum injections. The injections were applied a week apart in a single cycle and the cycles were 6 to 8 weeks apart. Patients were instructed to perform penile modelling (stretching and straightening) at home in between the cycles.

Results
The efficacy and side effects were evaluated at each visit and also 3 months after the last application. The satisfaction rate of treated men was extremely high and only two men reported no significant improvement and were scheduled for a surgical repair of penile curvature. There were no serious side effects reported, only some minor local changes in form of swelling and bruising of the penis.

Conclusions
Application of collagenase Clostridium histolyticum proved to be an effective and safe procedure for the treatment of Peyronie’s disease.

Conflicts of Interest
All authors declare no conflict of interest.
(131) CAN DELAYED EJACULATION HAVE AN IMPACT ON PSYCHOLOGICAL HEALTH? FINDINGS FROM A CROSS SECTIONAL STUDY
Authors: Christian Corsini , Federico Belladelli , Edoardo Pozzi , Fallara Giuseppe , Simone Cilio , Massimiliano Raffo , Fausto Negri , Ludovica Cella , Margherita Fantin , Alessandro Bertini , Francesco Lanzaro , Luigi Candela , Luca Boeri , Paolo Capogrosso , Alessia D'Arma , Francesco Montorsi , Andrea Salonia 
Published: July 2023

Abstract

Objectives
Delayed Ejaculation (DE) is among the most challenging male sexual dysfunctions. We aimed to explore and compare the sociodemographic and clinical characteristics of men with DE with those complaining of primary premature ejaculation (PE).

Methods
Data from 555 consecutive men seeking first medical help for DE and/or primary PE between 2005 and 2022 at a single tertiary-referral center were retrospectively analyzed. Complete socio-demographic, clinical and laboratory data were collected. All patients completed the International Index of Erectile Function (IIEF) and the Beck Depression Inventory (BDI) at baseline. We excluded men with known or potential causes responsible for ejaculatory disorders (n= 52). Descriptive statistics was used to detail and compare clinical and sociodemographic characteristics between the two groups (DE vs. PE). Linear regression models tested the association between depressive symptoms (BDI) and baseline IIEF domains scores among men with DE.

Results
Of 555 patients, 479 (86.3%) and 76 (13.7%) primary PE and DE, respectively. Men with DE were significantly older (44 vs. 47, p=0.01) than patients with PE. Conversely, the two groups did not differ in terms of educational/relational status, BMI, comorbidities, and hormonal milieu. At psychosexual interview, men with DE report more frequently symptoms referable to anxiety and depression (9.4% and 12,7%) along with higher median baseline BDI scores (8 vs. 6), all p&lt;0.01. DE patients reported lower median IIEF-OF, -SD domains (6 vs. 9) and (7 vs. 8) than patients with PE only, all p&lt;0.05. At linear regression analysis, among DE patients, a higher BDI score was associated with lower IIEF -OS (coeff.-1.57, CI[-2.60,-0.53], p&lt;0.004), and IS (coeff.-0.72, CI[-1.29,-0.16], p=0.01) domains (Figure 1). No association between BDI and IIEF-OF, -EF, -SD domains was found

Conclusions
Among men with complaining of ejaculatory disorders, one out of ten reports DE. These patients have higher chances to report clinically significant depression significantly impacting on their overall satisfactory sexual life.

Conflicts of Interest
None
(221) ON-DEMAND PAROXETINE FOR PREMATURE EJACULATION - SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Dr. Faisal Nawaz , Dr. Simon Williams 
Published: July 2023

Abstract

Objectives
This review aims to compare the efficacy of On-demand Paroxetine to on-demand Dapoxetine and Placebo for the treatment of Premature Ejaculation.

Review question
In patients with premature ejaculation, does on-demand Paroxetine increase the Intravaginal ejaculatory latency time compared to on-demand Dapoxetine therapy?

Methods
Electronic databases were systematically searched to identify the eligible Randomized Controlled Trials, comparing on-demand Paroxetine to Dapoxetine or placebo, following the Cochrane Collaboration methodology. Non-randomized trials were excluded.
The Protocol for this systematic review was prospectively registered on PROSPERO - International Prospective Register of Systematic Reviews with the reference number CRD42022316352.

Results
Highly sensitive search strategies were designed following the PRISMA-S guidelines to search the MEDLINE, Cochrane CENTRAL, EMBASE, PsycINFO, and other bibliographic databases. Subject terms (MeSH) "Premature Ejaculation", "Paroxetine", "Dapoxetine", and "on-demand" were adapted to each database for a comprehensive literature search. Results are reported in line with PRISMA guidelines. 1171 abstracts were identified for screening by two independent reviewers using the Covidence software. Full-text screening of the 30 records was performed. The meta-analysis included nine eligible randomized controlled trials, recruiting a total of 721 participants. Meta-analysis was performed using the Cochrane Collaboration's Review manager software.

Conclusions
Meta-analysis of the included studies favored on-demand Paroxetine over Dapoxetine; however, the IELT improvement was not statistically significant with the on-demand Paroxetine. There was a high degree of heterogeneity among the included trials. On-demand Paroxetine does not significantly prolong the IELT compared to the on-demand Dapoxetine and Placebo. Significant heterogeneity and inconsistencies were found among the included studies. The certainty of the evidence of study outcomes was affected mainly by the study limitations, imprecision, and small sample size. A well-designed, large RCT is required to provide further evidence to support this hypothesis.

Conflicts of Interest
Nothing to declare.
(281) TESTOSTERONE DEFICIENCY AND RISK OF COGNITIVE DISORDERS IN AGING MALES:RESULTS FROM A META-ANALYSIS STUDY
Authors: Dr. Walter Vena , Dr. Nicola Bianchi , Dr. Francesca Frizza , Prof. Giulia Rastrelli , Dr. Alessandra Sforza , Dr. Alessandro Brunetti , Dr. Alessandro Pizzocaro , Prof. Mario Maggi , Dr. Giovanni Corona 
Published: July 2023

Abstract

Objectives
The aim of the present study is to systematically meta-analyze and discuss all the available evidence regarding the possible role of Testosterone replacement therapy (TRT) in age-depended male cognition impairment and dementia.

Methods
A comprehensive Medline, Embase and Cochrane search was performed including the following words: [“testosterone”[MeSH Terms] OR “testosterone”[All Fields]] AND [“cognition”[MeSH Terms] OR “cognition”[All Fields]]. All placebo-controlled trials evaluating the effect of TRT on several cognition outcomes without any restriction were included. Since the classification of tests into cognitive domains differed among the included studies, the available neuropsychological tests were divided into seven cognitive domains, based on an established neuropsychological reference text as previously reported. In order to obtain more comparable results, only trials with homogenous cognitive tests were analyzed.

Results
Overall, 17 studies were available including 1438 patients with a mean age of 70.4 years and a mean follow-up of 45.6 weeks. These trials differ in basal TT levels and type of T preparation used. In addition, nine were performed in aging men without memory problems, five in subjects with mild to moderate cognitive impairment and two in patients with Alzheimer’s disease. When TRT was compared to placebo, no difference in all the cognitive domains analyzed was observed. In addition, no differences were also observed when depressive symptoms or score derived from Mini-Mental State Examination test were considered or when only patients with cognitive impairment were considered.

Conclusions
Present data did not support the use of TRT for the improvement of several cognitive domains analyzed including attention/working memory, executive function, language, verbal memory, visual memory, visuomotor ability, and visuospatial ability. However, it is important to recognize that the vast majority of available RCTs included mixed populations of subjects with eugonadism and hypogonadism preventing any final conclusions

Conflicts of Interest
No conflict of interest to declare.
(218) ONCO-MICROTESE IN PATIENTS SUFFERING FROM CONCOMITANT TESTICULAR CANCER AND AZOOSPERMIA: A SINGLE-CENTER EXPERIENCE
Authors: Dr. Alessandro Giordano , Dr. Angelo di Giovanni , Dr. Carlo D'alterio , Dr. Claudio Marino , Dr. Lorenzo Cirigliano , Dr. Luigi Napolitano , Dr. Federica Cariati , Dr. Roberto La Rocca , Prof. Alessandro Palmieri , Dr. Marco Capece 
Published: July 2023

Abstract

Objectives
Testicular cancer (TC) accounts for 1% of all tumors and 6-24% of these patients are azoospermic at diagnosis. Moreover in most of these patients, adjuvant chemotherapy results in a decreased spermatogenesis function. The aim of the present study is to report the outcomes of onco-microTESE in our center case series.

Methods
From January 2019 to September 2022 we enrolled eleven patients aged from twenty-four to thirty-nine affected by testicular cancer and azoospermia. The diagnosis of TC was made by physical examination, scrotal ultrasound and tumor markers (αFP, βHCG, LDH). Two semen analysis and evaluation of testosterone, FSH, LH, estradiol, prolactin were performed before treatment. After surgery, tumor volume (TuV) and testicular volume (TeV) were measured and the ratio between them was evaluated (TuV/TeV).
All patients underwent onco-microTESE with the help of an operator microscope and with the aid of a biologist in the surgery room.
Statistical analyses were performed to correlate FSH, TuV and TeV.

Results
Six out of eleven patients had high FSH level while the LH was normal in all patients. In five out of eleven patients testicular volume was &lt;12ml. Spermatozoa were successfully retrieved and frozen from 4/11 testes (36.36%). In all these cases TuV/TeV were &lt;0,1 and in three out of four patients FSH was normal

Conclusions
In conclusion onco-microTESE should be considered the gold standard for patients with concomitant azoospermia and TC. Despite the low number of patients enrolled due to the rarity of such a condition, we observed a positive correlation between normal FSH and TuV/TeV&lt;0,1 with surgical sperm retrieval (SSR). Further studies are required to evaluate the effective use of these parameters in preoperative evaluation of azoospermic patients with testicular tumors.

Conflicts of Interest
The Authors declair no conflict of interest.